AzTrials
AzTrials

HIVNCT02445846

Dual Rapid HIV & Syphilis Tests in Zambia

An observational study of HIV and Syphilis, run by University of North Carolina, Chapel Hill at 1 site in Zambia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to provide evidence on the performance and operational characteristics of commercially available dual HIV/syphilis Rapid Diagnostic Tests (RDTs) in Zambia for their introduction into antenatal care and other settings. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
HIV, Syphilis
What is being tested?
dual HIV/syphilis rapid diagnostics tests
Type of treatment
Medical device
How many people
3,010 participants
Where
1 siteZambia
Study dates
May 2014to Jan 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Pregnant women, regardless of HIV status, seeking antenatal care at Chipata, Chawama, or Kamwala District Health Centres in Lusaka, Zambia.

Who may be able to join

  • Pregnant women attending their first antenatal care visit at a study clinic
  • 18 years of age or older
  • Willing and able to provide informed consent for study participation

Who cannot join

  • Prior participation in the study

Trial locations and contacts

1 site in 1 country.

Zambia1 site
  • Centre for Infectious Disease Research in Zambia

    Lusaka

Other trials in Zambia

About this study

Official title: Field Performance Evaluation of Dual Rapid HIV & Syphilis Tests in Zambia

The purpose of this study is to provide evidence on the performance and operational characteristics of commercially available dual HIV/syphilis Rapid Diagnostic Tests (RDTs) in Zambia for their introduction into antenatal care and other settings.

Read the detailed description

Early detection and timely intervention of pregnant women infected with HIV and/or syphilis is critical. To improve the number of women tested and treated, the Centre for Infectious Disease Research in Zambia (CIDRZ) and the Ministry of Community Development, Mother and Health (MCDMCH) this field study will assess the effectiveness of newly developed dual HIV and syphilis rapid diagnostic tests (RDTs) manufactured by Chembio and Standard Diagnostics in Lusaka District antenatal clinics.

The specific objectives of this field performance evaluation of the rapid diagnostics are to determine the antenatal clinic-based performance of dual HIV/syphilis RDTs compared to that of current reference standard assays, and to assess the operational characteristics and acceptability of these dual HIV/syphilis RDTs to patients and health care providers This cross-sectional study of 3,765 pregnant women will validate the performance of Chembio and Standard Diagnostics dual HIV and Syphilis RDTs.

Conditions
HIV, Syphilis
Being tested
dual HIV/syphilis rapid diagnostics tests
Medical subject headings
Syphilis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • dual HIV/syphilis rapid diagnostics testsDevice

    Also called Chembio and Standard Disgnostics

Study groups in NCT02445846
Study groupRoleWhat they receive
Pregnant womenPregnant women, regardless of HIV status, seeking antenatal care at clinics in Lusaka, Zambia
Receives: Device: dual HIV/syphilis rapid diagnostics tests

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. performance of dual rapid HIV/syphilis tests

    The performance of the rapid study tests will be assessed by determining the specificity and the sensitivity when compared to reference standard assays

    Measured: day 1/enrollment

Secondary outcomes (1)
  1. acceptability of use of dual rapid HIV/syphilis tests

    the operational characteristics and acceptability of the tests to patients and health care providers will be measured.

    Measured: day 1/enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 May 2015 (estimated)
  2. Study startMay 2014
  3. Primary completionDec 2015
  4. Study completionJan 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
3,010 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02445846
Sponsor's protocol ID
14-0528
Status last verified
Feb 2017
First submitted
13 May 2015
Last updated
21 Apr 2017
Results posted
No
Data monitoring committee
No

Publications

  • Katepa-Bwalya M, Kankasa C, Babaniyi O, Siziya S. Effect of using HIV and infant feeding counselling cards on the quality of counselling provided to HIV positive mothers: a cluster randomized controlled trial. Int Breastfeed J. 2011 Sep 26;6:13. doi: 10.1186/1746-4358-6-13.

    PubMed 21943308
  • Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect. 2011 Apr;87(3):183-90. doi: 10.1136/sti.2010.047514. Epub 2011 Feb 17.

    PubMed 21330572
  • Lee MJ, Hallmark RJ, Frenkel LM, Del Priore G. Maternal syphilis and vertical perinatal transmission of human immunodeficiency virus type-1 infection. Int J Gynaecol Obstet. 1998 Dec;63(3):247-52. doi: 10.1016/s0020-7292(98)00165-9.

    PubMed 9989893
  • Mwapasa V, Rogerson SJ, Kwiek JJ, Wilson PE, Milner D, Molyneux ME, Kamwendo DD, Tadesse E, Chaluluka E, Meshnick SR. Maternal syphilis infection is associated with increased risk of mother-to-child transmission of HIV in Malawi. AIDS. 2006 Sep 11;20(14):1869-77. doi: 10.1097/01.aids.0000244206.41500.27.

    PubMed 16954728
  • WHO. Progress Report 2010; Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector; Chapter 5: Scaling Up HIV Services for Women and Children http://www.who.int/hiv/pub/2010progressreport/ch5_en.pdf. Accessed July 12, 2011.

  • Watson-Jones D, Changalucha J, Gumodoka B, Weiss H, Rusizoka M, Ndeki L, Whitehouse A, Balira R, Todd J, Ngeleja D, Ross D, Buve A, Hayes R, Mabey D. Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. J Infect Dis. 2002 Oct 1;186(7):940-7. doi: 10.1086/342952. Epub 2002 Sep 3.

    PubMed 12232834
  • Watson-Jones D, Gumodoka B, Weiss H, Changalucha J, Todd J, Mugeye K, Buve A, Kanga Z, Ndeki L, Rusizoka M, Ross D, Marealle J, Balira R, Mabey D, Hayes R. Syphilis in pregnancy in Tanzania. II. The effectiveness of antenatal syphilis screening and single-dose benzathine penicillin treatment for the prevention of adverse pregnancy outcomes. J Infect Dis. 2002 Oct 1;186(7):948-57. doi: 10.1086/342951. Epub 2002 Sep 3.

    PubMed 12232835
  • WHO. Global prevalence and incidence of selected curable sexually transmitted infections. Overview and estimates. Geneva: http://www.who.int/hiv/pub/sti/who_hiv_aids_2001.02.pdf. Accessed April 1, 2011.

  • McDermott J, Steketee R, Larsen S, Wirima J. Syphilis-associated perinatal and infant mortality in rural Malawi. Bull World Health Organ. 1993;71(6):773-80.

    PubMed 8313495
  • Di Mario S, Say L, Lincetto O. Risk factors for stillbirth in developing countries: a systematic review of the literature. Sex Transm Dis. 2007 Jul;34(7 Suppl):S11-21. doi: 10.1097/01.olq.0000258130.07476.e3.

    PubMed 17592385
  • Strasser S, Bitarakwate E, Gill M, Hoffman HJ, Musana O, Phiri A, Shelley KD, Sripipatana T, Ncube AT, Chintu N. Introduction of rapid syphilis testing within prevention of mother-to-child transmission of HIV programs in Uganda and Zambia: a field acceptability and feasibility study. J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):e40-6. doi: 10.1097/QAI.0b013e318267bc94.

    PubMed 22820810
  • Kettler H, White K, Hawkes S. Mapping the landscape of diagnostics for sexually transmitted infections. World Health Organization, Geneva, 2004.

Questions about this trial

What is this clinical trial studying?

An observational study of HIV and Syphilis, run by University of North Carolina, Chapel Hill at 1 site in Zambia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Zambia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

performance of dual rapid HIV/syphilis tests (time frame: day 1/enrollment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02445846, which also lists 12 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in